Vienna vaccine start-up to be acquired by MSD

Acquisition is expected to accelerate the development of a COVID-19 vaccine candidate

27-May-2020 - Themis and MSD (trademark of Merck & Co., Inc.) announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its ...

Zika & Chikungunya Vaccine Development Boosted By Cash Injection

Themis Bioscience successfully closed 10 Mio EUR financing round

30-Nov-2016 - Themis Bioscience successfully closed a Series B financing round of 10 Mio Euro. The fresh capital will be used to complete a phase 2 clinical trial of its lead product, a vaccine candidate against Chikungunya fever. Further products that will benefit include the company's Zika virus vaccine ...

Themis Bioscience’s Raises up to EUR 10 Million in Series B

07-May-2015 - Themis Bioscience announced the first closing of EUR 7 Million in a Series B financing of up to EUR 10 Million, led by new investor Wellington Partners. Existing investors Ventech and Omnes Capital (formerly Crédit Agricole Private Equity) also participated in the round. Dr Regina Hodits, General ...

Threat of emerging virus can be stopped

Interim results of first clinical trial of Themis Bioscience’s vaccine candidate against Chikungunya fever prove successful

16-Jun-2014 - A prophylactic vaccine candidate against Chikungunya fever, developed by Themis Bioscience GmbH induces a significant neutralizing immune response and was also confirmed as safe. These are the major interim results of a phase 1 clinical study of the company's Chikungunya vaccine candidate that ...